| Therapeutic | Obinutuzumab |
| Target | MS4A1 |
| Heavy Chain | QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS |
| Light Chain | DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK |
| 100% seqID Fv Structure | 3pp3 [Fvs: HL, IK], 3pp4 [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3pp3 [Fvs: HL, IK] |
| 100% seqID Structure | 3pp4 [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (June '19) | Approved |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | GlycoMAb Technology |
| INN Year Proposed | 2008 |
| INN Year Recommended | 2011 |
| Companies Involved | GLYCART Biotechnology, Biogen Idec, Chugai Pharmaceutical, Dana-Farber Cancer Institute, Genentech, Lymphoma Academic Research Organisation, Nippon Shinyaku, OHSU Knight Cancer Institute, Pharmacyclics, Polish Myeloma Consortium, Roche, Thomas Jefferson University, University of Heidelberg, University of Leeds |
| Conditions Approved | Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin's lymphoma |
| Conditions Active | Diffuse large B cell lymphoma, CNS cancer, Graft-versus-host disease, Lupus nephritis, Mantle-cell lymphoma, Waldenstrom's macroglobulinaemia |
| Conditions Discontinued | Primary biliary cirrhosis |
| Notes | Obinutuzumab and Afutuzumab are the same mAb |
